^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersBIOMARKER:
HER-2 negative + AR positive + ER positive
i
Other names: ERBB2, CD340, HER-2, HER2, NEU, NGL, V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2; ESR1, Era, ESR, NR3A1, ER, ER beta; AR, AIS, DHTR, HUMARA, NR3C4, SBMA, SMAX1, Androgen receptor
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
4d
CLEE011AIC01: A Study of Ribociclib in Combination With Hormonal Therapy in HR+/HER2- Advanced or Metastatic Breast Cancer (clinicaltrials.gov)
P=N/A, N=175, Completed, Novartis Pharmaceuticals | Recruiting --> Completed | N=550 --> 175
Trial completion • Enrollment change • HEOR • Real-world evidence
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
ER positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive
|
Kisqali (ribociclib)
6d
Trial of Anastrozole and Palbociclib in Metastatic HER2-Negative Breast Cancer (clinicaltrials.gov)
P2, N=40, Active, not recruiting, Wake Forest University Health Sciences | Trial completion date: Jun 2026 --> Jun 2028 | Trial primary completion date: Jun 2026 --> Jun 2028
Trial completion date • Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
ER positive • HER-2 negative • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive
|
Ibrance (palbociclib) • anastrozole
10d
Exploration of BMI and circulating metabolic factors as predictors of metformin benefit in CCTG MA.32. (PubMed, JNCI Cancer Spectr)
BMI and blood variables did not identify subgroups with luminal or triple negative bc who benefitted from metformin nor those with HER2 positive bc who did not benefit.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor) • CRP (C-reactive protein) • LEP (Leptin)
|
HER-2 positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive
|
metformin
13d
NIMBUS: Nivolumab Plus Ipilimumab in Metastatic Hypermutated HER2-negative Breast Cancer (clinicaltrials.gov)
P2, N=30, Active, not recruiting, Dana-Farber Cancer Institute | Trial completion date: Feb 2026 --> Feb 2027
Trial completion date • IO biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor) • TMB (Tumor Mutational Burden)
|
HR positive • HER-2 amplification • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive
|
MSK-IMPACT • OncoPanel™ Assay
|
Opdivo (nivolumab) • Yervoy (ipilimumab)
15d
UC-BCG-2513: Skipping Hormone Therapy in Low-Risk Early Breast Cancer (2025-523683-20-00)
P1/2, N=630, Not yet recruiting, Unicancer
New P1/2 trial
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
ER positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive
|
tamoxifen • letrozole • anastrozole • exemestane
18d
Phase III Trial of Camrelizumab+Apatinib+Eribulin vs. Physician's Choice Chemotherapy in Advanced Triple-Negative Breast Cancer (clinicaltrials.gov)
P3, N=246, Recruiting, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Active, not recruiting --> Recruiting | Trial completion date: Mar 2031 --> Jun 2029 | Trial primary completion date: Sep 2030 --> Dec 2028
Enrollment open • Trial completion date • Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
ER positive • HER-2 negative • ER negative • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive
|
AiRuiKa (camrelizumab) • AiTan (rivoceranib) • Halaven (eribulin mesylate)
18d
A Prospective, Cohort, Open Study of Immunoradiotherapy Combined with Cidarbenamide and PD-1 Monotherapy in the Backline Treatment of Advanced Solid Tumors (ChiCTR2300068737)
P4, N=67, Recruiting, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School; Nanjing Drum Tower Hospital, The Affiliated Hospital of Nan | Not yet recruiting --> Recruiting | Phase classification: PN/A --> P4 | N=35 --> 67
Enrollment open • Phase classification • Enrollment change
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
ER positive • HR positive • HER-2 negative • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive
|
Tyvyt (sintilimab) • Epidaza (chidamide)
20d
Pure Mucinous Breast Carcinoma: Integrating Molecular and Immunohistochemical Profiles for Accurate Diagnosis-A Case Report. (PubMed, Case Rep Oncol Med)
Pure MCB is a rare, low-grade tumor with distinct pathological features. Accurate diagnosis and complete surgical excision are essential for optimal management, as patients typically achieve excellent long-term outcomes.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
|
HER-2 negative • HER-2 negative + AR positive + ER positive
21d
Brain Radiotherapy Combined With Dalpiciclib and Endocrine Therapy in HR-Positive/HER2-Negative Advanced Breast Cancer With Brain Metastases (clinicaltrials.gov)
P2, N=46, Not yet recruiting, Nanfang Hospital, Southern Medical University
New P2 trial
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
ER positive • HR positive • HER-2 negative • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive
|
AiRuiKang (dalpiciclib)
27d
Ribociclib for HR-positive HER2-negative Metastatic Breast Cancer (clinicaltrials.gov)
P1/2, N=86, Recruiting, Nagoya City University | Not yet recruiting --> Recruiting
Enrollment open
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
ER positive • HR positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive
|
Kisqali (ribociclib) • anastrozole
27d
A Study on the Use of Fluzoparib Combined With Chemotherapy for Neoadjuvant Treatment of HRD-positive, HR+/HER2- Breast Cancer (clinicaltrials.gov)
P2, N=28, Completed, Xijing Hospital | Recruiting --> Completed | Trial completion date: Dec 2026 --> Mar 2026 | Trial primary completion date: Nov 2026 --> Feb 2026
Trial completion • Trial completion date • Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • HRD (Homologous Recombination Deficiency) • BRCA (Breast cancer early onset)
|
BRCA2 mutation • ER positive • BRCA1 mutation • HER-2 negative • HRD • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive
|
docetaxel • cyclophosphamide • AiRuiYi (fluzoparib)
1m
LaPemERLA: Phase II Lenvatinib and Pembrolizumab in Endocrine Resistant Breast Cancer With Letrozole (clinicaltrials.gov)
P2, N=40, Recruiting, National Cancer Centre, Singapore | Trial completion date: Dec 2027 --> Dec 2028 | Trial primary completion date: Dec 2025 --> Dec 2026
Trial completion date • Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
ER positive • HER-2 amplification • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive
|
Keytruda (pembrolizumab) • Lenvima (lenvatinib) • letrozole
Share via
